Publications in the NUM
Here you will find a list of publications that were written in connection with the Network of University Medicine in the first and second funding phases.
Jerg-Bretzke L,
Kempf M,
Jarczok MN,
Weimer K,
Hirning C,
Gündel H,
Erim Y,
Morawa E,
Geiser F,
Hiebel N,
Weidner K,
Beschoner P.
Psychosocial Impact of the COVID-19 Pandemic on Healthcare Workers and Initial Areas of Action for Intervention and Prevention—The egePan/VOICE Study.
International Journal of Environmental Research and Public Health.
2021;
18(19):10531.
[DOI]
Kluge S,
Malin JJ,
Fichtner F,
Müller OJ,
Skoetz N,
Karagiannidis C.
Recommendations on the In-Hospital Treatment of Patients With COVID-19.
Dtsch Arztebl Int.
2021;
[DOI]
Wagner KI,
et al .
Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection.
Cell reports.
2021;
35110214.
[DOI]
Bauer S,
Contreras S,
Dehning J,
Linden M,
Iftekhar E,
Mohr SB,
Olivera-Nappa A,
Priesemann V.
Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves.
PLOS Computational Biology.
2021;
17(9):e1009288.
[DOI]
Thole D,
Ole Diesterhöft T,
Vogel S,
Greve M,
Bauer E,
Strathmann S,
Elsner C,
Kolbe N,
Krefting D.
Relevant Aspects for Sustainable Open Source Pandemic Apps and Platform Deployment with Focus on Community Building.
Stud Health Technol Inform.
2021;
283186—193.
[DOI]
Ansems K,
Grundeis F,
Dahms K,
Mikolajewska A,
Thieme V,
Piechotta V,
Metzendorf M,
Stegemann M,
Benstoem C,
Fichtner F.
Remdesivir for the treatment of COVID‐19.
Cochrane Database of Systematic Reviews.
2021;
2021(8):CD014962.
[DOI]
Wurzer D,
Spielhagen P,
Siegmann A,
Gercekcioglu A,
Gorgass J,
Henze S,
Kolar Y,
Koneberg F,
Kukkonen S,
McGowan H,
Schmid-Eisinger S,
Steger A,
Dommasch M,
Haase HU,
Müller A,
Martens E,
Haller B,
Huster KM,
Schmidt G.
Remote monitoring of COVID-19 positive high-risk patients in domestic isolation: A feasibility study.
PLOS ONE.
2021;
16(9):e0257095.
[DOI]
[File]
Salholz-Hillel M,
Grabitz P,
Pugh-Jones M,
Strech D,
DeVito NJ.
Results availability and timeliness of registered COVID-19 clinical trials: interim cross-sectional results from the DIRECCT study.
BMJ Open.
2021;
11(11):e053096.
[DOI]
Nordsiek F,
Bodenschatz E,
Bagheri G,
et al .
Risk assessment for airborne disease transmission by poly-pathogen aerosols.
PLOS ONE.
2021;
[DOI]
Wunsch M,
Aschemeier D,
Hegera E,
et al .
Safe and effective pool testing for SARS-CoV-2 detection.
J Clin Virol.
2021;
145
[DOI]
Reis S,
Popp M,
Schmid B,
Stegemann M,
Metzendorf M,
Kranke P,
Meybohm P,
Weibel S.
Safety and Efficacy of Intermediate- and Therapeutic-Dose Anticoagulation for Hospitalised Patients with COVID-19: A Systematic Review and Meta-Analysis.
J Clin Med.
2021;
11(1):57.
[DOI]
Hillus D,
et al .
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
The Lancet Respiratory Medicine.
2021;
[DOI]
Pfefferle S,
Günther T,
Kobbe R,
Czech-Sioli M,
Nörz D,
Santer R,
Oh J,
Kluge S,
Oestereich L,
Peldschus K,
Indenbirken D,
Huang J,
Grundhoff A,
Aepfelbacher M,
Knobloch JK,
Lütgehetmann M,
Fischer N.
SARS Coronavirus-2 variant tracing within the first Coronavirus Disease 19 clusters in northern Germany.
Clinical Microbiology and Infection.
2021 Jan.;
27(1):130.e5—130.e8.
[DOI]
[File]
Möckel M,
Corman V,
Stegemann MS,
et al .
SARS-CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department.
Biomarker.
2021;
26(3):
[DOI]
Deinhardt-Emmer S,
Bottcher S,
Haring C,
Giebeler L,
Henke A,
Zell ea.
SARS-CoV-2 causes severe epithelial inflammation and barrier dysfunction.
J Virol.
2021;
Wendisch D,
et al .
SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.
Cell.
2021;
1846243-6261.e27.
[DOI]
Wendisch D,
Dietrich O,
Mari T,
et al .
SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.
Cell.
2021;
[DOI]
Wendisch D,
Dietrich O,
Mari T,
Stillfried S,
Ibarra I,
Mittermaier M,
Mache C,
Chua R,
Knoll R,
Timm S,
Stahl D.
SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.
Cell.
2021;
184(26):6243—6261.e27.
[DOI]
Wendisch D,
Dietrich O,
Mari T,
Stillfried S,
Ibarra IL,
Mittermaier ea.
SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.
Cell.
2021;
1846243—6261.e6227.
[DOI]
Jansen J,
Reimer K,
Nagai J,
et al .
SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids.
Cell Stem Cell.
2021;
[DOI]
Hoffmann M,
et al .
SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization.
Cell Reports.
2021;
35109017.
[DOI]
Malin JJ,
et al .
SARS-CoV-2 neutralizing antibody treatment in COVID-19 patients with immunodeficiency due to B-cell non-Hodgkin lymphoma.
Blood advances.
2021;
[DOI]
Schwarz T,
et al .
SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients.
Frontiers in immunology.
2021;
12629185.
[DOI]
Heinemann S,
Bludau A,
Kaba H,
Knolle P,
Grundmann H,
Scheithauer S.
SARS-CoV-2 surveillance and testing: results of a survey from the Network of University Hospitals (NUM), B-FAST.
GMS Hyg Infect Control.
2021;
16
[DOI]
Heinemann S,
Bludau A,
Kaba H,
Knolle P,
Grundmann H,
Scheithauer S.
SARS-CoV-2 surveillance and testing: results of a survey from the Network of University Hospitals (NUM), B-FAST.
GMS hygiene and infection control.
2021;
16Doc31.
[DOI]
Hoffmann M,
et al .
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.
Cell Reports.
2021;
36109415.
[DOI]
Hoffmann M,
et al .
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
Cell.
2021;
1842384-2393.e12.
[DOI]
Ondruschka B,
Püschel K,
Lange P,
Becker I,
Rieger-Ndakorerwa G,
Schröder AS.
SARS-CoV-2-assoziierte Hamburger Sterbefälle in der zweiten Pandemiewelle - Vergleich der bekannt gewordenen Todesfälle in den Gesundheitsämtern und der Rechtsmedizin.
Archiv für Kriminologie.
2021;
248(5/6):180—187.
[File]
Lohner L,
Fröb D,
Edler C,
Schröder AS,
Dietz E,
Ondruschka B.
SARS-CoV-2-assoziierte Todesfälle von erwachsenen Personen bis 50 Jahre: Eine retrospektive Auswertung der COVID-19-assoziierten Todesfälle im Jahr 2020 im Institut für Rechtsmedizin Hamburg, Deutschland [SARS-CoV-2-associated deaths in adult persons up to 50 years of age].
Rechtsmedizin (Berl).
2021;
1-9.
Gassen N,
Papies J,
Bajaj T,
Emanuel J,
Dethloff F,
Chua ea.
SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals.
Nat Commun.
2021;
123818.
Kreuzberger N,
Hirsch C,
Chai KL,
Tomlinson E,
Khosravi Z,
Popp M,
Neidhardt M,
Piechotta V,
Salomon S,
Valk SJ,
Monsef I,
Schmaderer C,
Wood EM,
So-Osman C,
Roberts DJ,
McQuilten Z,
Estcourt LJ,
Skoetz N.
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Cochrane Database Syst Rev.
2021;
9(9):CD013825.
[DOI]
Kreuzberger N,
et al .
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Cochrane Database of Systematic Reviews.
2021;
9CD013825.
[DOI]
Hirsch C,
et al .
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
Cochrane Database of Systematic Reviews.
2021;
[DOI]
Schmidt K,
et al .
SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses.
Frontiers in immunology.
2021;
12627568.
[DOI]
Gornyk D,
et al .
SARS-CoV-2-Seroprävalenz in Deutschland. Eine bevölkerungsbezogene sequenzielle Studie in sieben Regionen.
Dtsch Arztebl Int.
2021;
118824–831.
Klein A,
Langenwalder F,
Heinrich F,
Meißner K,
Schröder AS,
Püschel K,
Ondruschka B,
Lütgehetmann M,
Heinemann A.
SARS-CoV2-Zufallsentdeckungen bei Hamburger Todesfällen: ein epidemiologisches Monitoring während des dynamischen Infektionsgeschehens im Frühjahr 2020 [SARS-CoV2 incidental findings among Hamburg deaths: an epidemiological monitoring during the dynamic infection event in spring 2020].
Rechtsmedizin (Berl).
2021;
1-7.
Würstle S,
Spinner CD,
Voit F,
et al .
Self-sampling versus health care professional-guided swab collection for SARS-CoV-2 testing.
Infection.
2021;
49(5):
[DOI]
Schmuck J,
Hiebel N,
Rabe M,
Schneider J,
Erim Y,
Morawa E,
Jerg-Bretzke L,
Beschoner P,
Hannemann J,
Weidner K,
Steudte-Schmiedgen S,
Radbruch L,
Brunsch H,
Geiser F.
Sense of coherence, social support and religiosity as resources for medical personnel during the COVID-19 pandemic: A web-based survey among 4324 health care workers within the German Network University Medicine.
PLOS ONE.
2021;
16(7):
[DOI]
Steinbeis F,
Thibeault C,
Doellinger F,
Ring R,
Mittermaier M,
Ruwwe-Glösenkamp C,
Knape P,
Meyer H,
Lippert L,
Stahl D.
Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months.
Respir Med.
2021;
191106709.
[DOI]
Günl F,
Mecate-Zambrano A,
Rehländer S,
Hinse S,
Ludwig S,
Brunotte L.
Shooting at a Moving Target-Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development.
Vaccines (Basel).
2021;
9
Fischer D,
et al .
Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through 'reverse phenotyping'.
Nature Communications.
2021;
124515.
[DOI]
Wulff A,
Baier C,
Marschollek M,
et al .
SmICS: Eine smarte Lösung zur automatisierten Ausbruchserkennung im Krankenhaus.
Gesundhyte.
2021;
14
[File]
Schug C,
Morawa E,
Geiser F,
Hiebel N,
Beschoner P,
Jerg-Bretzke L,
Weidner K,
Steudte-Schmiedgen S,
Borho A,
Lieb M,
Erim Y.
Social Support and Optimism as Protective Factors for Mental Health among 7765 Healthcare Workers in Germany during the COVID-19 Pandemic: Results of the VOICE Study.
International Journal of Environmental Research and Public Health.
2021;
18(7):
[DOI]
[File]
Dragano N,
Hoebel J,
Wachtler B,
Diercke M,
Lunau T,
Wahrendorf M.
Soziale Ungleichheit in der regionalen Ausbreitung von SARS-CoV-2.
Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz.
2021;
641116—1124.
[DOI]